Seeking Alpha
10 Jun 2026, 01:22 UTC · 9h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Olema Pharmaceuticals expects the first readout from the OPERA-01 Phase 3 trial of palazestrant monotherapy in the fall. — Phase 3 results are primary catalysts for biotech valuation and potential regulatory approval pathways.
+0.80The company recently presented data at ASCO showing monotherapy activity for its KAT6/7 inhibitor in both ER-positive/HER2-negative breast cancer and castration-resistant prostate cancer. — Proof of concept in two distinct oncology indications expands the company's total addressable market.
+0.60Combination trials for the KAT6/7 inhibitor in breast cancer are ongoing, and trials for prostate cancer are set to begin. — Expansion into combination therapies suggests a broader clinical strategy and future growth potential.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is presenting clinical stage assets and expecting a Phase 3 readout in the fall, indicating positive progress in its pipeline.
Goldman Sachs is mentioned only as the host of the healthcare conference.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
GS showed up in this week’s NIS Momentum screen.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
5h ago
